November 29, 2016 - By Peter Kolinski
Jason Shandell, President and General Counsel of Amphastar Pharmaceuticals Inc is the insider, Octafinance want to tell you for. Mr. Jason submitted an electronic document with the D.C. based-SEC making public a sale for 26,335 shares of the stock exchange listed company, the one he is an insider in. At the time of the legal trading deal, the average market stock price of Amphastar Pharmaceuticals Inc was $20.5, making the dealing worth $539,258 U.S. Dollars. Currently, Jason Shandell owns 202,961 shares which are equivalent to about 0.44% of Amphastar Pharmaceuticals Inc’s market capitalization.
Out of 4 analysts covering Amphastar Pharmaceuticals (NASDAQ:AMPH), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. $20 is the highest target while $17 is the lowest. The $18.67 average target is -8.17% below today’s ($20.33) stock price. Amphastar Pharmaceuticals has been the topic of 8 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The stock of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) earned “Buy” rating by Zacks on Monday, August 10. On Tuesday, August 18 the stock rating was upgraded by Zacks to “Hold”. The firm has “Buy” rating by Jefferies given on Tuesday, August 9. The firm has “Outperform” rating given on Friday, February 19 by Wells Fargo. The stock has “Market Perform” rating given by BMO Capital Markets on Wednesday, June 29. Needham maintained the stock with “Buy” rating in Tuesday, May 10 report. Jefferies maintained it with “Buy” rating and $17 target price in Tuesday, January 19 report.
Insitutional Activity: The institutional sentiment increased to 3.17 in 2016 Q2. Its up 1.07, from 2.1 in 2016Q1. The ratio improved, as 7 funds sold all Amphastar Pharmaceuticals Inc shares owned while 23 reduced positions. 19 funds bought stakes while 44 increased positions. They now own 15.47 million shares or 11.85% more from 13.83 million shares in 2016Q1.
Eam Investors Lc has invested 0.6% of its portfolio in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH). The Texas-based Teacher Retirement Systems Of Texas has invested 0% in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH). Morgan Stanley, a New York-based fund reported 47,794 shares. Massachusetts Fincl Ma holds 45,886 shares or 0% of its portfolio. Allianz Asset Ag last reported 94,014 shares in the company. Proshare Advisors Ltd Liability Corp reported 37,737 shares or 0.01% of all its holdings. Hbk Investments Lp has 0% invested in the company for 11,157 shares. Federated Pa accumulated 0.07% or 1.48 million shares. New York State Common Retirement Fund, a New York-based fund reported 32,600 shares. Gotham Asset Mngmt Limited Liability Corp reported 19,579 shares or 0% of all its holdings. The New York-based Metropolitan Life Ins has invested 0% in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH). Moreover, Schwab Charles Mngmt Inc has 0% invested in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) for 72,893 shares. Bnp Paribas Arbitrage has 1,379 shares for 0% of their US portfolio. Da Davidson And Communication owns 8,975 shares or 0% of their US portfolio. Nationwide Fund Advsrs accumulated 0% or 51,240 shares.
Insider Transactions: Since June 9, 2016, the stock had 0 insider purchases, and 21 sales for $14.98 million net activity. $463,607 worth of shares were sold by Gerst Diane G. on Friday, August 19. $7,236 worth of shares were sold by Petersen Floyd F. on Tuesday, November 1. Shandell Jason B. had sold 10,000 shares worth $199,500 on Monday, August 22. The insider PETERS WILLIAM J sold $18,681. 444,199 shares with value of $9.34 million were sold by Zhang Jack Y. on Tuesday, September 20. 48,375 shares were sold by Shohet Stephen B., worth $882,281 on Friday, August 12. $784,680 worth of shares were sold by Lee Howard on Monday, November 14.
The stock decreased 0.10% or $0.02 during the last trading session, hitting $20.33. About 213,088 shares traded hands. Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) has risen 59.36% since April 26, 2016 and is uptrending. It has outperformed by 54.10% the S&P500.
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company has a market cap of $922.52 million. The Firm focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. It has a 45.04 P/E ratio. The Firm has two divisions: finished pharmaceutical products and active pharmaceutical ingredients products.
According to Zacks Investment Research, “Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.”
Analysts await Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) to report earnings on March, 13.
More news for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) were recently published by: Fool.com, which released: “Why Amphastar Pharmaceuticals, Inc. is Soaring Today” on September 20, 2016. Globenewswire.com‘s article titled: “Amphastar Pharmaceuticals to Present at the 2016 Piper Jaffray Healthcare ..” and published on November 28, 2016 is yet another important article.
Amphastar Pharmaceuticals, Inc., incorporated on May 19, 2004, is a specialty pharmaceutical company. The Firm focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Firm has two divisions: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment makes, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment makes and distributes recombinant human insulin and porcine insulin. The Firm makes and sells approximately 20 products. Additionally, the Company is developing a portfolio of approximately 10 generic abbreviated new drug applications (ANDA), over three generic biosimilar and over six injectable and inhalation product candidates.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.